Samsung Biologics is a fully integrated CDMO offering a mammalian cell line & process development to cGMP clinical & commercial manufacturing (DS/DP) and biosafety testing services, all from a single location. We provide highly tailored solutions to each client in need.
Established in April 2011, Samsung Biologics' core business activities include Upstream & Downstream Process Development, Clinical & Commercial manufacturing, Aseptic Fill/Finish, and Analytical & Biosafety testing. With our manufacturing sites located in South Korea, all plants are cGMP compliant holding 364KL total capacity with flexible clinical & commercial scales of 1KL, 5KL, 15KL.
With a dedicated Quality Control Lab & Process Development Unit and designed as multi-product facilities to meet the requirements of the US FDA, EMA, and other global regulatory agencies. Recently, 4KL of Single-use bioreactors have added, which provides us further flexibility to accommodate a wide range of clients' demands.
Sessions Featuring Samsung Biologics
Samsung Biologics' Company Presentation:
Key Considerations for Successful Technology Transfer (Andrew Kim, Associate Director of DSP MSAT)
BioProcess International Theater Sessions:
- Get to IND Faster: Accelerated & High Performance Cell Line Development (John Gill, Director of Cell Line Development)
- Economics of Stainless Steel and Single-Use Systems (Justin Carbungco, Associate Director, Small Commercial Manufacturing)
- Reinventing the CMO Client Experience: Case Studies in Adapting to the Industry and Client Needs (Richard Lee, Head of Drug Product Business Unit)
- BioProcess Insider Interviews: How Samsung Biologics is expanding its capabilities & improving business resilience in COVID-19 (Kevin Sharp, Head of Business Development)
- Panel Discussion: The evolving role of the outsourcing manufacturer: Why CDMO is the new normal (Dan Slone, VP & Head of Downstream Manufacturing)
And don't forget to meet Samsung Biologics in BIO One-on-One Partnering during BIO Digital Week.
